Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Clovis to Co-develop IVD for Drug Candidate

NEW YORK (GenomeWeb News) – Foundation Medicine and Clovis Oncology today announced a collaboration to develop an in vitro diagnostic test to identify cancer patients who may best respond to a Clovis drug candidate currently in phase I/II clinical development.

The companies will analyze genomic changes in tissue samples from patients in order to assess the possibility of developing an IVD method directed at Clovis' drug rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. Particularly, they said, they aim to identify the additional genetic mutations beyond those in germ-line and somatic BRCA associated with defective DNA repair and that may define tumor targets for rucaparib.

The collaboration may be able to increase the percentage of ovarian cancer patients potentially eligible for rucaparib therapy from 15 percent typically found in germ-line mutations of BRCA to about 40 percent to 50 percent who have DNA repair deficiencies due to somatic mutations in a variety of genes, Foundation and Clovis said.

Financial and other terms of the deal were not disclosed.

Today's deal marks the most recent between Foundation and a pharmaceutical firm in recent months in support of an oncology program, following agreements with Novartis, Array BioPharma, and Sanofi.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.